Do you want to access to this and other private contents?
Log in if you are a subscriber or click here to request service
Roche enters the field of anti-obesity research
Carmot acquires for 2.7 billion dollars: the Swiss company will work on hormones
Roche has stipulated a definitive agreement of fusion for the acquisition of Carmot Therapeutics, private American company with center to Berkeley, in California. Carmot’s research and development portfolio includes clinical subcutaneous and oral incretine for the treatment of obesity in patients with and without diabetes, as well as a number of preclinical programs. Incretine are intestinal hormones se...
EFA News - European Food Agency